ProCE Banner Activity

My Insights on the Latest Data on Tumor-Infiltrating Lymphocytes in Melanoma and Clinical Applications of TIL Therapy

Clinical Thought

Learn about the latest data on adoptive cellular technology using tumor-infiltrating lymphocytes (TILs) and how TIL therapy may fit into the current treatment paradigm for advanced melanoma.

Released: February 14, 2023

Expiration: February 13, 2024

Share

Faculty

Allison Betof Warner

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Iovance Biotherapeutics

Faculty Disclosure

Primary Author

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

Allison Betof Warner, MD, PhD: consultant/advisor/speaker: Bristol-Myers Squibb, Instil Bio, Iovance, Lyell Immunopharma, Novartis, Pfizer, Shanghai Jo'Ann Medical Technology.